Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › aromatase inhibitor

aromatase inhibitor

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of aromatase inhibitor

10 trials tracked of aromatase inhibitor: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 166 citations.

10Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 4 Other / NA 3
  1. Phase 3 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Completed · 166 cited
  2. Phase 3 Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature Completed · 99 cited
  3. Phase 4 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed
  4. Phase 2 Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer Completed
  5. Phase 2 Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer Completed
  6. Phase 2 A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer Completed
Show 4 more trials
  1. Phase 2 Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer Completed
  2. N/A Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor Completed
  3. N/A Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. Completed
  4. N/A Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer
Oncology Phase II
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer New Drug Combo Helps Breast Cancer After CDK4/6 Failure
This phase 2 trial evaluated tucidinostat plus metronomic capecitabine with endocrine therapy in 66 patients with HR-positive HER2-negative …
A new drug mix shrinks tumors in advanced breast cancer patients whose disease grew after standard treatments failed.
Apr 17, 2026